NEW YORK (GenomeWeb) – Veracyte said after the close of the market on Tuesday that it is planning a public offering of 5 million shares of its common stock.

The molecular diagnostics firm will also grant underwriters a 30-day option to purchase up to 750,000 additional shares.

Veracyte said it plans to use the net proceeds for working capital and other corporate purposes, and that it may also use some of the proceeds to acquire or invest in complementary businesses or technologies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Mar
20
Sponsored by
Qiagen

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Mar
21
Sponsored by
Loop Genomics

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Mar
26
Sponsored by
PerkinElmer

This webinar will address the current status and future directions for massively high-throughput genomics for plant and animal breeding and research.